Search
Perth investigators involved in a major global trial have launched an innovative Cultural Information Hub to maximise cultural safety for Aboriginal and/or Torres Strait Islander patients participating in research.
Whooping Cough Day in 2025 has a special significance to Catherine Hughes AM and her family - it marks a decade of dedication to vaccine advocacy after the loss of their four-week-old baby son Riley in 2015.
Eight outstanding researchers from The Kids Research Institute Australia and the Institute-led Broome STEM Festival are finalists in the 2025 Premier’s Science Awards.
Western Australian kids will have access to a needle-free nasal flu vaccine for the first time in 2026 as part of a new initiative to boost vaccination rates against the life-threatening virus.
Papua New Guinean researcher Dr Lincoln Timinao has been awarded the 2025 Deborah Lehmann Research Award (DLRA) for his work aimed at investigating the burden of malaria in young children.
Wesfarmers Centre of Vaccines and Infectious Diseases researchers Dr Janessa Pickering and Dr August Mikucki travelled to Broome last week for the official launch of the long-awaited Missing Piece story books.
Antifungal prophylaxis can reduce morbidity and mortality from invasive fungal disease (IFD). However, its use needs to be optimised and appropriately targeted to patients at highest risk to derive the most benefit. In addition to established risks for IFD, considerable recent progress in the treatment of malignancies has resulted in the development of new 'at-risk' groups.
Patients with haematological malignancies, haemopoietic stem cell transplant recipients and patients requiring admission to intensive care settings are at high risk for invasive candidiasis (IC). Over the past decade, there has been increased reporting of non-albicans species and fluconazole resistance in Australia. These guidelines provide updated evidence-based recommendations for the diagnosis and management of IC in adult and paediatric haematology, oncology and intensive care settings.
Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.